StockNews.com downgraded shares of Perrigo (NYSE:PRGO – Free Report) from a buy rating to a hold rating in a report published on Tuesday.
Other equities analysts have also recently issued research reports about the stock. Piper Sandler lowered their price objective on shares of Perrigo from $36.00 to $35.00 and set an overweight rating on the stock in a research note on Thursday, July 11th. Canaccord Genuity Group reaffirmed a buy rating and issued a $42.00 price objective on shares of Perrigo in a research note on Friday, April 12th.
Check Out Our Latest Stock Analysis on PRGO
Perrigo Stock Up 0.1 %
Perrigo (NYSE:PRGO – Get Free Report) last released its quarterly earnings results on Saturday, May 4th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.06. Perrigo had a negative net margin of 0.17% and a positive return on equity of 6.96%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the firm earned $0.45 EPS. Perrigo’s revenue was down 8.4% on a year-over-year basis. On average, analysts forecast that Perrigo will post 2.56 earnings per share for the current fiscal year.
Perrigo Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 18th. Stockholders of record on Friday, May 31st were paid a $0.276 dividend. The ex-dividend date was Friday, May 31st. This represents a $1.10 annualized dividend and a dividend yield of 3.93%. Perrigo’s dividend payout ratio is currently -1,571.43%.
Insider Transactions at Perrigo
In other news, EVP Svend Andersen bought 1,000 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were acquired at an average cost of $27.90 per share, with a total value of $27,900.00. Following the completion of the transaction, the executive vice president now directly owns 101,853 shares in the company, valued at approximately $2,841,698.70. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.70% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in PRGO. Raymond James & Associates increased its position in shares of Perrigo by 78.7% in the fourth quarter. Raymond James & Associates now owns 169,789 shares of the company’s stock worth $5,464,000 after acquiring an additional 74,782 shares in the last quarter. Pacer Advisors Inc. grew its position in Perrigo by 78.5% during the fourth quarter. Pacer Advisors Inc. now owns 20,364 shares of the company’s stock valued at $655,000 after purchasing an additional 8,958 shares in the last quarter. Blue Trust Inc. grew its position in Perrigo by 34.5% during the fourth quarter. Blue Trust Inc. now owns 1,556 shares of the company’s stock valued at $50,000 after purchasing an additional 399 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its position in Perrigo by 4.1% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 9,627 shares of the company’s stock valued at $310,000 after purchasing an additional 380 shares in the last quarter. Finally, Pinnacle Associates Ltd. grew its position in Perrigo by 29.2% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,435 shares of the company’s stock valued at $368,000 after purchasing an additional 2,585 shares in the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.
Perrigo Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
See Also
- Five stocks we like better than Perrigo
- With Risk Tolerance, One Size Does Not Fit All
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What is the NASDAQ Stock Exchange?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Quiet Period Expirations Explained
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.